Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1021 - A Multicenter Phase II Trial of Paclitaxel, Carboplatin and Cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Head and Neck Cancers


Tomohiro Enokida


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


T. Enokida1, T. Ogawa2, A. Homma3, K. Okami4, S. Minami5, S. Iwae6, A. Nakanome2, Y. Shimizu7, A. Motegi8, D. Maki4, Y. Ueda1, T. Fujisawa1, S. Nomura9, S. Okano1, M. Tahara1

Author affiliations

  • 1 Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Otolaryngology And Head And Neck Surgery, Tohoku University School of Medicine, 980-8574 - Sendai/JP
  • 3 Department Of Otolaryngology, Head & Neck Surgery, Hokkaido University Graduate School of Medicine, 060-8648 - Sapporo/JP
  • 4 Department Of Otolaryngology-head Neck Surgery, Tokai University, 259-1193 - Isehara/JP
  • 5 Department Of Otorhinolaryngology, National Hospital Organization Tokyo Medical Center, 152-8902 - Tokyo/JP
  • 6 Head And Neck Surgery, Hyogo Cancer Center, Akashi/JP
  • 7 Department Of Medical Oncology, Hokkaido University Hospital, 060-8648 - Sapporo/JP
  • 8 Division Of Radiation oncology And Particle Therapy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 9 Clinical Biostatistics Division, Center For Research Administration And Support, National Cancer Center, 277-8577 - Kashiwa/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1021


Induction chemotherapy (IC) often compromises the compliance of following chemoradiotherapy (CRT) in LA-SCCHN. In particular, impaired compliance of cisplatin (CDDP) during CRT negatively affects outcomes. Here, we aimed to assess the feasibility and efficacy of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN.


Patients with biopsy-proven, unresectable LA-SCCHN were enrolled. IC consisted of CBDCA AUC = 1.5, PTX 80mg/m2 and Cmab with an initial dose of 400mg/m2 followed by 250mg/m2 administered weekly for 8 weeks. Following IC, CDDP (20mg/m2, 4 days x 3 cycles) and concurrent radiotherapy (70Gy/35fr) were started. Primary endpoint was the rate of CRT completion, defined by (1) completion of planned CDDP relative dose intensity (RDI) ≥ 80%, and (2) completion of radiotherapy within 2 weeks after planned completion date. PCE was planned to be deemed effective if the Bayesian posterior probability (PP) that the rate of CRT completion was > 65% exceeded 84%.


35 patients were eligible and received study treatment. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all Stage IV (stage IVA: 24, stage IVB: 11). Of 35 patients, 34 (97%) completed IC and 32 received CRT (FAS). Of 32 FAS cases, the rate of CRT completion was 96.9%, and the study’s primary endpoint was therefore met (PP = 99.9% > 84%). Mean cumulative dose and RDI of CDDP in CRT was 232.5mg (160-240mg) and 100% (66.7-100%), respectively. Response rate was 88.6% in the IC phase and 93.8% in the CRT phase. 2-year rates of local progression, distant metastasis, event-free survival and overall survival were 34.9%, 16.7%, 55.1% and 83.5%, respectively. Main grade 3 toxicities included neutropenia (11%), skin rash (6%), and anemia (6%) in the IC phase; and oral mucositis (31%), neutropenia (13%), and radiation dermatitis (13%) in the CRT phase. No grade 4 toxicity or treatment-related death was seen.


PCE as IC was feasible, with promising efficacy and no effect on compliance of following CRT in unresectable LA-SCCHN. A Phase III comparison with CRT alone is warranted.

Clinical trial identification


Legal entity responsible for the study

IC-PCE Study Executive Committee.


National Cancer Center Research and Development Fund (25-B-2).

Editorial Acknowledgement


K. Okami: Honoraria: Merck Serono Co, Ltd; Consulting or advisory role: Merck Serono Co, Ltd. S. Minami: Speakers’ bureau: Nihon Cochlear; Research funding: Taiho Pharmaceutical, Kyorin Pharmaceutical. S. Iwae: Research funding: Ono Pharmaceutical CO, Ltd, Otsuka Pharmaceutical CO, Ltd. S. Nomura: Employment: Asahi Kasei Pharma (Immediate Family Member). S. Okano: Honoraria: Merck Serono, Brystol-Myers Squibb, Ono Pharmaceutical Co, Nippon Kayaku Co. M. Tahara: Honoraria: Bristol-Myers Squibb, Ono Pharmaceutical CO, Ltd, Merck Serono Co, Ltd, Eisai Co, Ltd, AstraZeneca PLC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.